• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Comment on: Dual therapy combining raltegravir with etravirine maintains a high level of viral suppression over 96 weeks in long-term experienced HIV-infected individuals over 45 years on a PI-based regimen: results from the Phase II ANRS 163 ETRAL study.

作者信息

Del Puente Filippo, Berruti Marco, Riccardi Niccolò, Di Biagio Antonio

机构信息

Department of Health Science (DISSAL), Infectious Disease Clinic, University of Genoa, Genoa, Italy.

Department of Infectious Diseases, Galliera Hospital, Genoa, Italy.

出版信息

J Antimicrob Chemother. 2020 Dec 1;75(12):3698-3699. doi: 10.1093/jac/dkaa120.

DOI:10.1093/jac/dkaa120
PMID:32285104
Abstract
摘要

相似文献

1
Comment on: Dual therapy combining raltegravir with etravirine maintains a high level of viral suppression over 96 weeks in long-term experienced HIV-infected individuals over 45 years on a PI-based regimen: results from the Phase II ANRS 163 ETRAL study.评论：在基于蛋白酶抑制剂的治疗方案中，将拉替拉韦与依曲韦林联合进行双重治疗，可使45岁以上长期接受治疗的HIV感染者在96周内维持较高水平的病毒抑制：II期ANRS 163 ETRAL研究结果
J Antimicrob Chemother. 2020 Dec 1;75(12):3698-3699. doi: 10.1093/jac/dkaa120.
2
Dual therapy combining raltegravir with etravirine maintains a high level of viral suppression over 96 weeks in long-term experienced HIV-infected individuals over 45 years on a PI-based regimen: results from the Phase II ANRS 163 ETRAL study-authors' response.在基于蛋白酶抑制剂的治疗方案中，将拉替拉韦与依曲韦林联合使用的双重疗法，在45岁以上长期接受治疗的HIV感染个体中，96周内可维持较高水平的病毒抑制：II期ANRS 163 ETRAL研究结果——作者回应
J Antimicrob Chemother. 2020 Dec 1;75(12):3699-3700. doi: 10.1093/jac/dkaa341.
3
Dual therapy combining raltegravir with etravirine maintains a high level of viral suppression over 96 weeks in long-term experienced HIV-infected individuals over 45 years on a PI-based regimen: results from the Phase II ANRS 163 ETRAL study.在基于蛋白酶抑制剂的方案中，拉替拉韦与依曲韦林联合治疗可在 96 周内保持长期经验丰富的 45 岁以上 HIV 感染者高水平的病毒抑制：来自 II 期 ANRS 163 ETRAL 研究的结果。
J Antimicrob Chemother. 2019 Sep 1;74(9):2742-2751. doi: 10.1093/jac/dkz224.
4
Lack of a Clinically Significant Pharmacokinetic Interaction between Etravirine and Raltegravir Using an Original Approach Based on Drug Metabolism, Protein Binding, and Penetration in Seminal Fluid: A Pharmacokinetic Substudy of the ANRS-163 ETRAL Study.基于药物代谢、蛋白结合和精液穿透的原始方法评估依曲韦林与雷特格韦无临床显著药代动力学相互作用：ANRS-163 ETRAL 研究的药代动力学子研究。
Pharmacotherapy. 2019 Apr;39(4):514-520. doi: 10.1002/phar.2242. Epub 2019 Apr 1.
5
Characterization of viral rebounds on dual etravirine/raltegravir maintenance therapy (ANRS-163 ETRAL trial).双依非韦伦/拉替拉韦维持治疗时的病毒学反弹特征（ANRS-163 ETRAL 试验）。
J Antimicrob Chemother. 2020 Jul 1;75(7):1943-1949. doi: 10.1093/jac/dkaa090.
6
Once-daily etravirine/raltegravir (400/800 mg q24h) dual therapy maintains viral suppression over 48 weeks in HIV-infected patients switching from a twice-daily etravirine/raltegravir (200/400 mg q12h) regimen.对于从每日两次依曲韦林/雷特格韦（200/400毫克，每12小时一次）方案转换过来的HIV感染患者，每日一次依曲韦林/雷特格韦（400/800毫克，每24小时一次）双联疗法在48周内维持病毒抑制。
J Antimicrob Chemother. 2021 Jan 19;76(2):477-481. doi: 10.1093/jac/dkaa423.
7
Fat gain differs by sex and hormonal status in persons living with suppressed HIV switched to raltegravir/etravirine.在转为使用拉替拉韦/依曲韦林的 HIV 受抑制患者中，体脂增加存在性别和激素状态差异。
AIDS. 2020 Oct 1;34(12):1859-1862. doi: 10.1097/QAD.0000000000002644.
8
Addition of Etravirine Does Not Enhance the Initial Decline of HIV-1 RNA in Treatment-Experienced Patients Receiving Raltegravir.对于接受拉替拉韦治疗的有治疗经验的患者，添加依曲韦林并不会增强HIV-1 RNA的初始下降。
J Acquir Immune Defic Syndr. 2017 Aug 1;75(4):448-454. doi: 10.1097/QAI.0000000000001435.
9
Maintenance of Viral Suppression after Optimization Therapy from Etravirine Plus Raltegravir to Rilpivirine Plus Dolutegravir in HIV-1-Infected Patients.在HIV-1感染患者中，从依曲韦林加雷特格韦向利匹韦林加度鲁特韦优化治疗后病毒抑制的维持情况。
J Int Assoc Provid AIDS Care. 2019 Jan-Dec;18:2325958218821657. doi: 10.1177/2325958218821657.
10
Highly frequent HIV-1 minority resistant variants at baseline of the ANRS 139 TRIO trial had a limited impact on virological response.在 ANRS 139 TRIO 试验的基线时，高度频繁的 HIV-1 少数耐药变异体对病毒学反应的影响有限。
J Antimicrob Chemother. 2015 Jul;70(7):2090-6. doi: 10.1093/jac/dkv048. Epub 2015 Mar 8.

引用本文的文献

1
Effectiveness and Safety Analysis of PIs/r Based Dual Therapy in Treatment-Naïve, HIV/AIDS Patients: A Network Meta Analysis of Randomized Controlled Trials.初治HIV/AIDS患者中基于蛋白酶抑制剂/利托那韦的双重疗法的有效性和安全性分析：一项随机对照试验的网状Meta分析
Front Pharmacol. 2022 Mar 4;13:811357. doi: 10.3389/fphar.2022.811357. eCollection 2022.
2
In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing.基于药物再利用的分子对接和动力学模拟预测 SARS-CoV-2 主要蛋白酶的潜在抑制剂的计算机预测。
J Infect Public Health. 2020 Sep;13(9):1210-1223. doi: 10.1016/j.jiph.2020.06.016. Epub 2020 Jun 16.